Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT02345304
- Locations
- 🇩🇪
1344.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02342717
- Locations
- 🇩🇪
1346.10.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 329
- Registration Number
- NCT02337907
- Locations
- 🇫🇷
HOP La Pitié Salpêtrière, Paris, France
🇩🇪Praxis Dr. med. Volker Schumann, Berlin, Germany
🇫🇷HOP Pellegrin, Bordeaux, France
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2016-03-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT02337283
- Locations
- 🇩🇪
1346.2.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany
Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02331277
- Locations
- 🇰🇷
1293.9.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02305901
- Locations
- 🇩🇪
1307.20.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain
- Conditions
- Low Back Pain
- Interventions
- Drug: placebo matching nonivamide + nicoboxil (Finalgon cream)
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 138
- Registration Number
- NCT02300311
- Locations
- 🇺🇦
69.53.53202 Boehringer Ingelheim Investigational Site, Kyiv, Ukraine
🇺🇦69.53.53203 Boehringer Ingelheim Investigational Site, Kyiv, Ukraine
🇷🇺69.53.53103 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation
Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10
- Registration Number
- NCT02300298
- Locations
- 🇯🇵
1199.90.81006 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
🇯🇵1199.90.81001 Boehringer Ingelheim Investigational Site, Chiba , Kashiwa, Japan
🇯🇵1199.90.81003 Boehringer Ingelheim Investigational Site, Kanagawa, Yokohama, Japan
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7903
- Registration Number
- NCT02296138
- Locations
- 🇺🇸
1237.19.10003 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸1237.19.10021 Boehringer Ingelheim Investigational Site, Medford, Oregon, United States
🇨🇦1237.19.20021 Boehringer Ingelheim Investigational Site, Moncton, New Brunswick, Canada
GIOTRIF rPMS in Korean Patients With NSCLC
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1272
- Registration Number
- NCT02285361